Three-phase pharmaceutical form with constant and controlled release of amorphous active ingredient for single daily application
First Claim
1. A three-phase pharmaceutical form with constant and controlled release of amorphous active ingredient for a single daily peroral application characterized in that it contains a core consisting of a first and a second phase whereinthe first phase contains a mixture of an amorphous active ingredient in an amount from 0.05 mg to 300 mg, a water-soluble polymer polyvinylpyrrolidone in the range from 1 to 40 wt. % with respect to the total weight of the pharmaceutical form a surfactant in the ran(c from 0.1 to 20 wt % with respect to the total weight of the pharmaceutical form and a cellulose ether in the range from 10 to 70 wt % with respect to the total weight of the pharmaceutical form, said first phase being homogeneously mixed withthe second phase containing a cellulose ether in the range from 5 to 40 wt % with respect to the total weight of the pharmaceutical form, a mixture of mono-, di- and triglycerides in the range flow 0 to 10 wt % with respect to the total weight of the pharmaceutical form and usual adjuvants;
- wherein the weight ratio between the water soluble polymer polyvinylpyrrolidone and the cellulose ether in the first phase is in the range from 1;
10 to 10;
1, the weight ratio between the amor-phous active ingredient, the water soluble polymer polyvinylpyrrolidone and the cellulose ether in the first phase is in the range from 1;
20;
30 to 10;
2;
1, and the weight ratio between the cellulose ether of the first phase having an average molecular weight in the range of 5000 g/mol to 50000 g/mol and the cellulose ether of the second phase having an average molecular weight in the range of 50000 g/mol to 300000 g/mol is in the range of 5;
1 to 1;
5;
and a third phase surrounding the core and represented by a coating, said third phase being at film coating consisting of an ester of hydroxypropylmethylcellulose with phthalic anhydride in the weight ratio of the coating with respect to the core ranging from 2 to 10 wt % or of a copolymerizate of methacrylic acid and ethyl acrylate in the weight ratio of the coating with respect to the core in the range from 2 to 15 wt % and usual adjuvants.
1 Assignment
0 Petitions
Accused Products
Abstract
Described is a novel three-phase pharmaceutical form with constant and controlled release of an amorphous active ingredient stabilized with polymers for a single daily peroral application, which is especially suitable for active ingredients existing in amorphous form or in one or more polymorphous forms, which exhibit poor solubility in crystal form depending on the polymorphous form, particle size and the specific surface area of the active ingredient. The active ingredient can be used in its amorphous or any polymorphous form, which in the process of the preparation of the three-phase pharmaceutical form according to the invention is converted into the amorphous form. The three-phase pharmaceutical form with constant and controlled release of an amorphous active ingredient for a single daily peroral application contains a core consisting of a first and a second phase and a coating representing the third phase. In the first phase the three-phase pharmaceutical form contains an amorphous active ingredient, the water-soluble polymer polyvinylpyrrolidone and a cellulose ether as carriers of the amorphous active ingredient and simultaneously as inhibitors of its crystallization, a surfactant that improves the solubility of the active ingredient and promotes the absorption of the amorphous active ingredient from gastrointestinal tract, in the second phase it contains a cellulose ether and a mixture of mono-, di- and triglycerides as sustained release agents and the third phase is represented by a poorly soluble or gastro-resistant film coating, which in the first few hours after the application controls the release of the active ingredient and can consist of an ester of hydroxypropylmethylcellulose with phthalic anhydride or of a copolymerizate based on methacrylic acid and ethyl acrylate. Described is also a process for the preparation of this pharmaceutical form.
-
Citations
63 Claims
-
1. A three-phase pharmaceutical form with constant and controlled release of amorphous active ingredient for a single daily peroral application characterized in that it contains a core consisting of a first and a second phase wherein
the first phase contains a mixture of an amorphous active ingredient in an amount from 0.05 mg to 300 mg, a water-soluble polymer polyvinylpyrrolidone in the range from 1 to 40 wt. % with respect to the total weight of the pharmaceutical form a surfactant in the ran(c from 0.1 to 20 wt % with respect to the total weight of the pharmaceutical form and a cellulose ether in the range from 10 to 70 wt % with respect to the total weight of the pharmaceutical form, said first phase being homogeneously mixed with the second phase containing a cellulose ether in the range from 5 to 40 wt % with respect to the total weight of the pharmaceutical form, a mixture of mono-, di- and triglycerides in the range flow 0 to 10 wt % with respect to the total weight of the pharmaceutical form and usual adjuvants; -
wherein the weight ratio between the water soluble polymer polyvinylpyrrolidone and the cellulose ether in the first phase is in the range from 1;
10 to 10;
1, the weight ratio between the amor-phous active ingredient, the water soluble polymer polyvinylpyrrolidone and the cellulose ether in the first phase is in the range from 1;
20;
30 to 10;
2;
1, and the weight ratio between the cellulose ether of the first phase having an average molecular weight in the range of 5000 g/mol to 50000 g/mol and the cellulose ether of the second phase having an average molecular weight in the range of 50000 g/mol to 300000 g/mol is in the range of 5;
1 to 1;
5;and a third phase surrounding the core and represented by a coating, said third phase being at film coating consisting of an ester of hydroxypropylmethylcellulose with phthalic anhydride in the weight ratio of the coating with respect to the core ranging from 2 to 10 wt % or of a copolymerizate of methacrylic acid and ethyl acrylate in the weight ratio of the coating with respect to the core in the range from 2 to 15 wt % and usual adjuvants. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 43)
-
-
33. A process for the preparation of a three-phase pharmaceutical from with constant and controlled release of amorphous active ingredient for a single daily peroral application, containing a core consisting of a first and second phase wherein
the first phase contains a mixture of an amorphous active ingredient in an amount from 0.05 mg to 300 mg, the water-soluble polymer polyvinylpyrrolidone in the range from 1 to 40 wt. % with respect to the total weight of the pharmaceutical form, a surfactant in the range from 0.1 to 20 wt % with respect to the total weight of the pharmaceutical form and a cellulose ether in the range from 10 to 70 wt % with respect to the total weight of the pharmaceutical form, said first phase being homogeneously mixed with the second phase containing a cellulose ether in the range from 5 to 40 wt % with respect to the total weight of the pharmaceutical form, a mixture of mono- di- and triglycerides in the range form 0 to 10 wt % with respect to the total weight of the pharmaceutical form and usual adjuvants; -
wherein the weight ratio between the water soluble polymer polyvinylpyrrolidone and the cellulose ether in the first phase is in the range from 1;
10 to 10;
1, the weight ratio between the amorphous active ingredient, the water soluble polymer polyvinylpyrrolidone and the cellulose ether in the first phase is in the range from 1;
20;
30 to 10;
2;
1, and the weight ratio between the cellulose ether of the first phase having an average molecular weight in the range of 5000 g/mol to 50000 g/mol and the cellulose ether of the second phase having an average molecular weight in the range of 50000 g/mol to 300000 g/mol is in the range off 5;
1 to 1;
5and at third phase surrounding, the core and represented by a coating, said third phase being a film coating consisting of an ester of hydroxypropylmethylcellulose with phthalic anhydride in the weight ratio of the coating with respect to the core ranging from 2 to 10 wt % or of a copolymerizate of methacrylic acid and ethyl acrylate in the weight ratio of the coating with respect to the core in the range from 2 to 15 wt % and usual adjuvants, wherein an active ingredient, a surfactant and the water-soluble polymer polyvinylpyrrolidone are dissolved in an organic solvent at a temperature from 30°
C. to 70°
C. in a fluid bed granulator the resulting solution is sprayed onto cellulose ether in the fluid bed, the obtained granulate is homogeneously mixed with a cellulose ether and other usual adjuvants at room temperature and the granulate is compressed into tablets, which are coated with at film coating. - View Dependent Claims (34, 35, 36, 37, 38, 39, 40, 41, 42, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63)
-
Specification